Therapy Detail

Therapy Name Docetaxel + Carboplatin
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Carboplatin Paraplatin CBDCA Chemotherapy - Platinum 6 Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).
Docetaxel Taxotere Docetaxel anhydrous|Docefrez Antimicrotubule Agent 11 Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01779050 Phase II Trastuzumab Docetaxel Epirubicin + Cyclophosphamide Paclitaxel Fluorouracil + Epirubicin + Cyclophosphamide Docetaxel + Carboplatin Docetaxel + Cyclophosphamide Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Active, not recruiting
NCT00588770 Phase III Bevacizumab Docetaxel + Cisplatin Cisplatin + Fluorouracil Docetaxel + Carboplatin Carboplatin + Fluorouracil Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting